NeOnc Technologies Reports Investor Call on Phase 2a NEO100‑01 Results

What Happened
NeOnc Technologies Holdings, Inc. announced that it hosted an investor conference call on August 12, 2026 to discuss results from the Phase 2a portion of its clinical candidate NEO100‑01. The company filed an 8‑K on August 13, 2026 (Item 7.01) furnishing a transcript of that investor call as Exhibit 99.1.

Key Details

• Filed Form 8‑K on August 13, 2026 disclosing a Regulation FD investor call held August 12, 2026.
• Subject of the call: results from the Phase 2a portion of NEO100‑01 (clinical trial update).
• Transcript of the investor call is furnished as Exhibit 99.1 to the 8‑K.
• The filing is a disclosure of the call/transcript; it does not attach financial statements or new financial results.

Why It Matters
This filing gives investors access to management’s public discussion and details about NEO100‑01’s Phase 2a progress—important for assessing clinical development momentum. Because the 8‑K furnishes the call transcript, shareholders and analysts can review management’s remarks and any Q&A for clarity on trial outcomes, next steps, and timelines. The 8‑K itself does not report earnings or new financial figures.